Ebopiprant is a Small Molecule owned by Organon, and is involved in 4 clinical trials, of which 2 were completed, 1 is ongoing, and 1 is planned.
OBE-022 acts by antagonizing Prostaglandin F2 alpha (PGF2a) receptors. The receptor belongs to the G-protein coupled receptor family. Activation and stimulation of myometrium leads to increased uterine contractility. The drug candidate by blocking PGF2a receptors provides tocolytic effect for women in preterm labour to postpone the premature birth.
The revenue for Ebopiprant is expected to reach a total of $236m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Ebopiprant NPV Report.
Ebopiprant (OBE-022) is under development for the treatment of premature labor (tocolysis). The drug candidate is administered orally. It is a small molecule inhibitor of prostaglandin F2 alpha (PGF2alpha) receptor. It is a new chemical entity (NCE). It was also under development for severe dysmenorrhea.
ObsEva is a clinical-stage biopharmaceutical company that develops and commercializes drugs for women’s reproductive health and pregnancy. The company’s product portfolio comprises pipeline products for controlling preterm labor by reducing inflammation, decreasing uterine contractions, and preventing cervical changes and membrane ruptures; for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women and to decrease contractions, improve uterine blood flow and enhance the receptivity of the endometrium to embryo implantation. ObsEva is headquartered in Geneva, Switzerland.
The company reported revenues of (US Dollars) US$20.1 million for the fiscal year ended December 2021 (FY2021). The operating loss of the company was US$54.5 million in FY2021, compared to an operating loss of US$79.7 million in FY2020. The net loss of the company was US$58.4 million in FY2021, compared to a net loss of US$83 million in FY2020. The company reported revenues of US$3.7 million for the third quarter ended September 2022, an increase of 42.1% over the previous quarter.
Quick View – Ebopiprant
|Highest Development Stage|